

Kristian Reich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/118868/publications.pdf>

Version: 2024-02-01

252
papers

26,078
citations

5896

81
h-index

7160

153
g-index

261
all docs

261
docs citations

261
times ranked

10555
citing authors

#	ARTICLE	IF	CITATIONS
1	Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1521-1530.	2.2	25
2	Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. <i>Journal of Dermatological Treatment</i> , 2022, 33, 219-228.	2.2	17
3	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1652-1660.	2.2	20
4	Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 977-987.e14.	2.9	66
5	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2317-2324.	2.2	17
6	The hair follicle-psoriasis axis: Shared regulatory mechanisms and therapeutic targets. <i>Experimental Dermatology</i> , 2022, 31, 266-279.	2.9	6
7	Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis*. <i>British Journal of Dermatology</i> , 2022, 186, 466-475.	1.5	41
8	Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 1-11.	6.7	15
9	Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. <i>Dermatology and Therapy</i> , 2022, 12, 61-78.	3.0	18
10	Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial*. <i>British Journal of Dermatology</i> , 2022, 186, 942-954.	1.5	22
11	Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00698.	1.3	34
12	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials. <i>Acta Dermato-Venereologica</i> , 2022, 102, adv00683.	1.3	9
13	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	4.1	12
14	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis. <i>British Journal of Dermatology</i> , 2022, , .	1.5	1
15	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE 2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	2.4	8
16	Measuring patient-relevant benefits in the treatment of psoriasis with the Patient Benefit Index: development and preliminary validation of a 10-item short form. <i>British Journal of Dermatology</i> , 2022, 187, 588-589.	1.5	3
17	Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO. <i>Dermatology and Therapy</i> , 2022, 12, 203-221.	3.0	9
18	Molecular diagnostics in dermatology: An online survey to study usage, obstacles and requirements in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 287-295.	0.8	7

#	ARTICLE	IF	CITATIONS
19	Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis. <i>Dermatology and Therapy</i> , 2022, 12, 233-241.	3.0	4
20	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD _{1,2}): a clinical outcome measure for the severity of atopic dermatitis. <i>British Journal of Dermatology</i> , 2022, 187, 531-538.	1.5	13
21	Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence?. <i>British Journal of Dermatology</i> , 2022, 187, 591-593.	1.5	3
22	Contact sensitization to essential oils: <sc>IVDK</sc> data of the years 2010â€“2019. <i>Contact Dermatitis</i> , 2022, 87, 71-80.	1.4	8
23	Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4). <i>British Journal of Dermatology</i> , 2022, 187, 338-352.	1.5	32
24	Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5â€“year results from the randomized placeboâ€“controlled TRANSFIGURE study*. <i>British Journal of Dermatology</i> , 2021, 184, 425-436.	1.5	36
25	Longâ€“term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placeboâ€“controlled studies. <i>British Journal of Dermatology</i> , 2021, 184, 640-651.	1.5	16
26	Secukinumab 2â€“weekly vs. 4â€“weekly dosing in patients with plaqueâ€“type psoriasis: results from the randomized GAIN study*. <i>British Journal of Dermatology</i> , 2021, 184, 849-856.	1.5	16
27	Longâ€“term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3â€“year results from two randomized phase III trials (CIMPASIâ€“1 and CIMPASIâ€“2). <i>British Journal of Dermatology</i> , 2021, 184, 652-662.	1.5	15
28	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINEâ€“2 and â€“3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 450-457.	2.4	14
29	Immunogenicity of biologic therapies in psoriasis: Myths, facts and a suggested approach. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 329-337.	2.4	13
30	Time to relapse after tildrakizumab withdrawal in patients with moderateâ€“toâ€“severe psoriasis who were responders at week 28: <i>post hoc</i> analysis through 64â€“weeks from reSURFACE 1 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 919-927.	2.4	15
31	The value of subcutaneous vs. oral methotrexate: realâ€“world data from the German psoriasis registry PsoBest. <i>British Journal of Dermatology</i> , 2021, 184, 765-767.	1.5	8
32	Mouse models of atopic dermatitis: a critical reappraisal. <i>Experimental Dermatology</i> , 2021, 30, 319-336.	2.9	30
33	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderateâ€“toâ€“severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021, 184, 548-550.	1.5	4
34	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 476-485.	2.4	101
35	A phase 4, randomized, headâ€“toâ€“head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderateâ€“toâ€“severe plaque psoriasis (CHANGE). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 701-711.	2.4	13
36	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. <i>Lancet, The</i> , 2021, 397, 487-498.	13.7	139

#	ARTICLE	IF	CITATIONS
37	Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values 1, 2, 3 or 5 derived from a statistical conversion method. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1161-1175.	2.4	13
38	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 281-317.	2.4	84
39	Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet, The, 2021, 397, 475-486.	13.7	136
40	Spesolimab, an Anti-Interleukin-36 Receptor Antibody, in Patients with Palmoplantar Pustulosis: Results of a Phase IIa, Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study. Dermatology and Therapy, 2021, 11, 571-585.	3.0	55
41	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study*. British Journal of Dermatology, 2021, 185, 1160-1168.	1.5	21
42	IL17A/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study. Lancet, The, 2021, 397, 1564-1575.	13.7	73
43	Quality of psoriasis care in Germany – results from the nationwide health care studies PsoHealth 2004-2017. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1536-1542.	2.4	18
44	POS1031 – LOW INCIDENCE OF GASTROINTESTINAL-RELATED AND OVERALL SERIOUS ADVERSE EVENTS AMONG GUSELKUMAB-TREATED PATIENTS: POOLED ANALYSES OF VOYAGE 1 & 2 AND DISCOVER 1 & 2 THROUGH 1-YEAR. Annals of the Rheumatic Diseases, 2021, 80, 787-788.	0.9	0
45	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. British Journal of Dermatology, 2021, 185, 323-334.	1.5	55
46	A multicentre open-label study of apremilast in palmoplantar pustulosis (APLANTUS). Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2045-2050.	2.4	13
47	Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders. JAMA Dermatology, 2021, 157, 691.	4.1	59
48	Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2021, 397, 2169-2181.	13.7	199
49	Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab. Journal of Investigative Dermatology, 2021, 141, 1707-1718.e9.	0.7	62
50	German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 2: Treatment monitoring and specific clinical or comorbid situations. JDDG - Journal of the German Society of Dermatology, 2021, 19, 1092-1115.	0.8	20
51	Bimekizumab versus Adalimumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 130-141.	27.0	114
52	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2034-2044.	2.4	6
53	Transcriptomic Analysis of Blaschko-Linear Psoriasis Reveals Shared and Distinct Features with Psoriasis Vulgaris. Journal of Investigative Dermatology, 2021, , .	0.7	1
54	Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 142-152.	27.0	173

#	ARTICLE	IF	CITATIONS
55	Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study. <i>British Journal of Dermatology</i> , 2021, 185, 1124-1134.	1.5	21
56	Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2409-2414.	2.4	6
57	Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*. <i>British Journal of Dermatology</i> , 2021, 185, 1146-1159.	1.5	36
58	Short-Term Efficacy of Biologic Therapies in Moderate-to-Severe Plaque Psoriasis: A Systematic Literature Review and an Enhanced Multinomial Network Meta-Analysis. <i>Dermatology and Therapy</i> , 2021, 11, 1965-1998.	3.0	14
59	IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). <i>BMJ Open</i> , 2021, 11, e049822.	1.9	31
60	Which PASI Outcome Is Most Relevant to the Patients in Real-World Care?. <i>Life</i> , 2021, 11, 1151.	2.4	6
61	Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study. <i>British Journal of Dermatology</i> , 2020, 182, 304-315.	1.5	33
62	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.5	103
63	Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab. <i>British Journal of Dermatology</i> , 2020, 182, 180-189.	1.5	22
64	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	1.2	155
65	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. <i>British Journal of Dermatology</i> , 2020, 182, 869-879.	1.5	31
66	Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE 2 comparator study versus adalimumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 617-623.	2.2	10
67	Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. <i>British Journal of Dermatology</i> , 2020, 182, 1359-1368.	1.5	20
68	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
69	A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. <i>British Journal of Dermatology</i> , 2020, 182, 1348-1358.	1.5	117
70	Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 936-945.	1.2	71
71	Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1161-1173.	2.4	32
72	Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure. <i>Dermatology and Therapy</i> , 2020, 10, 133-150.	3.0	51

#	ARTICLE	IF	CITATIONS
73	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 877-884.	2.9	242
74	A new treatment option for paediatric psoriasis. <i>British Journal of Dermatology</i> , 2020, 183, 606-607.	1.5	0
75	Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 1333.	4.1	194
76	15057 Safety of baricitinib in patients with atopic dermatitis: Results of pooled data from two phase 3 monotherapy randomized, double-blind, placebo-controlled 16-week trials (BREEZE-AD1 and) Tj ETQq0 0 0 rgBT /Overlock 103f 50 617		
77	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020, 30, 267-278.	0.6	10
78	COVID-19 and implications for dermatological and allergological diseases. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 815-824.	0.8	30
79	Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL). <i>Dermatology and Therapy</i> , 2020, 10, 1099-1109.	3.0	13
80	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 881-890.	6.7	24
81	A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque psoriasis treated with biologics in a REAL world setting (PSO-BIO-REAL). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2566-2573.	2.4	19
82	Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 431-447.	3.0	40
83	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020, 15, e0235091.	2.5	17
84	Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase 3 trials. <i>British Journal of Dermatology</i> , 2020, 183, 242-255.	1.5	277
85	The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 839-846.	1.2	78
86	EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2461-2498.	2.4	149
87	FRIO272...SECUKINUMAB DEMONSTRATES A CONSISTENT SAFETY PROFILE IN PATIENTS WITH PSORIASIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS OVER LONG TERM: UPDATED POOLED SAFETY ANALYSES. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 722.2-722.	0.9	2
88	FRIO087...DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 621.1-621.	0.9	1
89	Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Analysis from a Long-term Clinical Study. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2020, 13, 18-22.	0.1	5
90	Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 831-839.	13.7	250

#	ARTICLE	IF	CITATIONS
91	Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 147-152.	0.7	2
92	Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2305-2312.	2.4	40
93	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 576-586.	13.7	198
94	Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2437-2446.e1.	0.7	70
95	Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. <i>Journal of Dermatology</i> , 2019, 46, 1141-1152.	1.2	9
96	Immunoglobulin E Selective Immunoabsorption Reduces Peripheral and Skin-Bound Immunoglobulin E and Modulates Cutaneous IL-13 Expression in Severe Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2019, 139, 720-723.	0.7	8
97	Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 2082-2086.	2.4	8
98	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in psoriasis patients treated up to 5 years. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1733-1741.	2.4	20
99	Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. <i>Arthritis Research and Therapy</i> , 2019, 21, 111.	3.5	215
100	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, e352-e353.	2.4	3
101	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1098-1106.	2.4	19
102	Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 473-479.	0.9	143
103	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2019, 182, 67-75.	1.5	7
104	Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. <i>British Journal of Dermatology</i> , 2019, 181, 859-862.	1.5	7
105	Efficacy and safety of mirikizumab (<sc>LY</sc> 3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase <sc>II</sc> study. <i>British Journal of Dermatology</i> , 2019, 181, 88-95.	1.5	65
106	OP0114...MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM. , 2019, , .		1
107	Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 333-339.	2.4	50
108	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019, 181, 358-365.	1.5	42

#	ARTICLE	IF	CITATIONS
109	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Phase III VOYAGE 1 and VOYAGE 2 Studies. American Journal of Clinical Dermatology, 2019, 20, 155-164.	6.7	37
110	Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled <sc>TRANSFIGURE</sc> trial. British Journal of Dermatology, 2019, 181, 954-966.	1.5	84
111	Gender and age significantly determine patient needs and treatment goals in psoriasis – a lesson for practice. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 700-708.	2.4	78
112	Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized <sc>VOYAGE</sc> 1 and <sc>VOYAGE</sc> 2 studies. British Journal of Dermatology, 2019, 180, 1039-1049.	1.5	57
113	Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. Journal of the American Academy of Dermatology, 2019, 80, 70-79.e3.	1.2	77
114	Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 546-552.	2.4	29
115	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.2	77
116	Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1940-1949.	2.4	62
117	Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). British Journal of Dermatology, 2018, 178, 674-681.	1.5	80
118	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. British Journal of Dermatology, 2018, 178, 1083-1101.	1.5	380
119	Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 397-402.	2.4	47
120	The genetic basis for most patients with pustular skin disease remains elusive. British Journal of Dermatology, 2018, 178, 740-748.	1.5	82
121	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 3-14.	2.4	76
122	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. British Journal of Dermatology, 2018, 179, 1385-1391.	1.5	25
123	Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. Journal of Investigative Dermatology, 2018, 138, 2168-2173.	0.7	41
124	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. British Journal of Dermatology, 2018, 179, 1205-1207.	1.5	69
125	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. British Journal of Dermatology, 2018, 179, 615-622.	1.5	57
126	S3 Guideline for the treatment of psoriasis vulgaris, update – Short version part 1 – Systemic treatment. JDDG - Journal of the German Society of Dermatology, 2018, 16, 645-669.	0.8	107

#	ARTICLE	IF	CITATIONS
127	Exposure-Response Modeling to Characterize the Relationship Between Ixekizumab Serum Drug Concentrations and Efficacy Responses at Week 12 in Patients With Moderate to Severe Plaque Psoriasis. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1489-1500.	2.0	10
128	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 418-431.	1.2	554
129	Psoriasis and metabolic syndrome in children: current data. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 131-136.	1.3	25
130	Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1014-1020.	2.4	18
131	Secukinumab initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2017, 177, 879-881.	1.5	26
132	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE) <i>Tj ETQq0 0,0 rgBT /Overlock 10</i>	13.7	428
133	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. <i>British Journal of Dermatology</i> , 2017, 177, 1024-1032.	1.5	48
134	Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. <i>British Journal of Dermatology</i> , 2017, 177, 1014-1023.	1.5	155
135	Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1693-1699.	2.4	18
136	The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1196-1207.	2.4	33
137	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1686-1692.	2.4	60
138	Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1483-1490.	2.4	33
139	Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. <i>British Journal of Dermatology</i> , 2017, 177, 587-590.	1.5	10
140	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). <i>British Journal of Dermatology</i> , 2017, 177, 197-205.	1.5	36
141	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 441-448.e2.	1.2	86
142	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 528-537.	13.7	94
143	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 855-862.	1.2	104
144	European S3 Guideline on the systemic treatment of psoriasis vulgaris Update Apremilast and Secukinumab in cooperation with EDF in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1951-1963.	2.4	116

#	ARTICLE	IF	CITATIONS
145	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". Journal of Investigative Dermatology, 2017, 137, 2642-2644.	0.7	2
146	The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 507-517.	2.4	156
147	Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3). Journal of Dermatological Treatment, 2017, 28, 282-287.	2.2	40
148	Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits minimal immunogenicity in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2017, 176, 752-758.	1.5	47
149	Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 294-303.	2.4	12
150	Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data. Journal of the American Academy of Dermatology, 2017, 76, 432-440.e17.	1.2	111
151	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. Journal of the American Academy of Dermatology, 2017, 76, 60-69.e9.	1.2	258
152	Methods for Imputing Missing Efficacy Data in Clinical Trials of Biologic Psoriasis Therapies: Implications for Interpretations of Trial Results. Journal of Drugs in Dermatology, 2017, 16, 734-741.	0.8	12
153	FRI0460...Secukinumab Shows Significant Efficacy in Nail Psoriasis: Week 32 Results from The Transfigure Study. Annals of the Rheumatic Diseases, 2016, 75, 603.2-604.	0.9	9
154	Quality of psoriasis care in Germany: results of the national health care study "PsoHealth". Archives of Dermatological Research, 2016, 308, 401-408.	1.9	41
155	Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 83-98.e4.	1.2	264
156	Clinical meaningfulness of complete skin clearance in psoriasis. Journal of the American Academy of Dermatology, 2016, 75, 77-82.e7.	1.2	96
157	Treatment Satisfaction in Psoriasis: Development and Use of the PsoSat Patient Questionnaire in a Cross-Sectional Study. Dermatology, 2016, 232, 334-343.	2.1	12
158	The German National Program on Psoriasis Health Care 2005-2015: results and experiences. Archives of Dermatological Research, 2016, 308, 389-400.	1.9	47
159	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology, 2016, 175, 273-286.	1.5	378
160	Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). JDDG - Journal of the German Society of Dermatology, 2016, 14, 50-57.	0.8	19
161	Retrospektive Datenerhebung der Psoriasis-Behandlung mit Fumarsäureestern bei Kindern und Jugendlichen in Deutschland (KIDS FUTURE-Studie). JDDG - Journal of the German Society of Dermatology, 2016, 14, 50-58.	0.8	9
162	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. New England Journal of Medicine, 2016, 375, 345-356.	27.0	670

#	ARTICLE	IF	CITATIONS
163	Panimmunoglobulin and IgE-selective extracorporeal immunoabsorption in patients with severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1882-1884.e6.	2.9	25
164	Patient-relevant treatment goals in psoriasis. <i>Archives of Dermatological Research</i> , 2016, 308, 69-78.	1.9	92
165	Calcium spirulan derived from <i>Spirulina platensis</i> inhibits herpes simplex virus 1 attachment to human keratinocytes and protects against herpes labialis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 197-203.e3.	2.9	68
166	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2015, 173, 930-939.	1.5	236
167	Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. <i>Experimental Dermatology</i> , 2015, 24, 529-535.	2.9	157
168	Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. <i>Dermatology</i> , 2015, 231, 35-40.	2.1	126
169	European S3 Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – in cooperation with EADV and IPC. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2277-2294.	2.4	353
170	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. <i>Archives of Dermatological Research</i> , 2015, 307, 875-883.	1.9	124
171	Treatment goals in psoriasis routine care. <i>Archives of Dermatological Research</i> , 2015, 307, 445-449.	1.9	29
172	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1156-1163.	2.4	20
173	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the) <i>Tj ETQq1 1 0.784314 rgBT /Overlock</i> 73, 37-49.	1.2	498
174	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 400-409.	1.2	472
175	A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. <i>New England Journal of Medicine</i> , 2015, 373, 136-144.	27.0	270
176	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and) <i>Tj ETQq0 0.0 rgBT /Overlock</i>	13.7	719
177	Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. <i>British Journal of Dermatology</i> , 2015, 172, 1371-1383.	1.5	179
178	Non-adherence and measures to improve adherence in the topical treatment of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 4-9.	2.4	63
179	Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. <i>British Journal of Dermatology</i> , 2014, 170, 591-598.	1.5	51
180	Treatment adherence: a hurdle for real-life effectiveness in psoriasis?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-3.	2.4	7

#	ARTICLE	IF	CITATIONS
181	Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. <i>Immunology</i> , 2014, 141, 133-142.	4.4	200
182	Assessing adherence factors in patients under topical treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ). <i>Archives of Dermatological Research</i> , 2014, 306, 287-297.	1.9	38
183	Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. <i>British Journal of Dermatology</i> , 2014, 171, 1123-1128.	1.5	120
184	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014, 170, 435-444.	1.5	37
185	Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). <i>British Journal of Dermatology</i> , 2014, 170, 425-434.	1.5	24
186	Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1670-1675.	2.4	75
187	Development of an adherence-enhancing intervention in topical treatment termed the topical treatment optimization program (TTOP). <i>Archives of Dermatological Research</i> , 2014, 306, 667-676.	1.9	20
188	A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 438-453.	2.4	122
189	Secukinumab in Plaque Psoriasis – Results of Two Phase 3 Trials. <i>New England Journal of Medicine</i> , 2014, 371, 326-338.	27.0	1,675
190	Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 871-881.e30.	1.2	423
191	Deutsches Psoriasis-Register PsoBest: Zielsetzung, Methodik und Basisdaten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014, 12, 48-58.	0.8	29
192	Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2). <i>British Journal of Dermatology</i> , 2013, 168, 1325-1334.	1.5	94
193	An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. <i>British Journal of Dermatology</i> , 2013, 168, 374-380.	1.5	16
194	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5-years of follow-up. <i>British Journal of Dermatology</i> , 2013, 168, 844-854.	1.5	350
195	Arzneimittelversorgung von Kindern mit Psoriasis in Deutschland. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 751-755.	0.8	5
196	Drug supply for children with psoriasis in Germany. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 751-755.	0.8	12
197	The interpretation of long-term trials of biologic treatments for psoriasis: trial designs and the choices of statistical analyses affect ability to compare outcomes across trials. <i>British Journal of Dermatology</i> , 2013, 169, 1198-1206.	1.5	15
198	Genetic diagnostics in inflammatory dermatoses - from insights into pathophysiology to individualized patient management. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 59-67.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Genetische Diagnostik bei entzündlichen Dermatosen - vom Einblick in die Pathophysiologie zur Möglichkeit eines individualisierten Managements. JDDG - Journal of the German Society of Dermatology, 2013, 11, 60-68.	0.8	18
200	Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. Journal of the American Academy of Dermatology, 2012, 66, 742-751.	1.2	124
201	Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 373-381.	2.4	44
202	The concept of psoriasis as a systemic inflammation: implications for disease management. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 3-11.	2.4	253
203	Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. British Journal of Dermatology, 2012, 166, 179-188.	1.5	177
204	S3 " Guidelines on the treatment of psoriasis vulgaris (English version). Update. JDDG - Journal of the German Society of Dermatology, 2012, 10, S1-95.	0.8	235
205	Methotrexate therapy in dermatology. JDDG - Journal of the German Society of Dermatology, 2012, 10, 363-370.	0.8	1
206	Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab [®] certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension. British Journal of Dermatology, 2012, 167, 180-190.	1.5	131
207	German S3-guidelines on the treatment of psoriasis vulgaris (short version). Archives of Dermatological Research, 2012, 304, 87-113.	1.9	96
208	Nail psoriasis as a severity indicator: results from the PsoReal study. Patient Related Outcome Measures, 2011, 2, 1.	1.2	38
209	Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: Results from PHOENIX 2. Journal of Dermatological Treatment, 2011, 22, 337-347.	2.2	44
210	Improvement of treatment-refractory atopic dermatitis by immunoadsorption: A pilot study. Journal of Allergy and Clinical Immunology, 2011, 127, 267-270.e6.	2.9	50
211	The Long-Term Safety of Adalimumab Treatment in Moderate to Severe Psoriasis. American Journal of Clinical Dermatology, 2011, 12, 321-337.	6.7	62
212	Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study. British Journal of Dermatology, 2011, 165, 399-406.	1.5	45
213	Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1). British Journal of Dermatology, 2011, 165, 1109-1117.	1.5	159
214	Strategies for improving the quality of care in psoriasis with the use of treatment goals " a report on an implementation meeting. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 1-13.	2.4	44
215	In touch with psoriasis: topical treatments and current guidelines. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 3-8.	2.4	59
216	What is new in topical therapy for psoriasis?. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 15-20.	2.4	28

#	ARTICLE	IF	CITATIONS
217	Therapie der Psoriasis im Kindes- und Jugendalter - ein deutscher Experten-Konsens. JDDG - Journal of the German Society of Dermatology, 2011, 9, 815-824.	0.8	29
218	S3 - Guidelines on the treatment of psoriasis vulgaris Update 2011. JDDG - Journal of the German Society of Dermatology, 2011, 9, S1-S95.	0.8	66
219	Immunologic Effects and Tolerability Profile of In-Season Initiation of a Standardized-Quality Grass Allergy Immunotherapy Tablet: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial in Adults with Grass Pollen-Induced Rhinoconjunctivitis. Clinical Therapeutics, 2011, 33, 828-840.	2.5	25
220	Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. British Journal of Dermatology, 2011, 164, 862-872.	1.5	121
221	Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of Dermatological Research, 2011, 303, 1-10.	1.9	690
222	A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis. New England Journal of Medicine, 2011, 365, 1586-1596.	27.0	182
223	Epidemiology and comorbidity of psoriasis in children. British Journal of Dermatology, 2010, 162, 633-636.	1.5	375
224	Nail psoriasis in Germany: epidemiology and burden of disease. British Journal of Dermatology, 2010, 163, 580-585.	1.5	160
225	Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany. Acta Dermato-Venereologica, 2010, 90, 147-151.	1.3	265
226	Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. Journal of the American Academy of Dermatology, 2010, 63, 571-579.	1.2	115
227	Psoriasis - New Insights Into Pathogenesis and Treatment. Deutsches Ärztblatt International, 2009, 106, 11-8, quiz 19.	0.9	61
228	Evaluation of Quality of Care and Guideline-Compliant Treatment in Psoriasis. Dermatology, 2009, 219, 54-58.	2.1	42
229	A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. British Journal of Dermatology, 2009, 160, 170-176.	1.5	73
230	Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. British Journal of Dermatology, 2009, 160, 1040-1047.	1.5	341
231	Ustekinumab. Nature Reviews Drug Discovery, 2009, 8, 355-356.	46.4	20
232	Wirksamkeit und Sicherheit von FumarsÃureestern in der Langzeittherapie der Psoriasis - Eine retrospektive Studie (FUTURE). JDDG - Journal of the German Society of Dermatology, 2009, 7, 603-611.	0.8	94
233	Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 683-691.	2.4	159
234	Approach to managing patients with nail psoriasis. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 15-21.	2.4	100

#	ARTICLE	IF	CITATIONS
235	European S3â€ Guidelines on the systemic treatment of psoriasis vulgaris. Journal of the European Academy of Dermatology and Venereology, 2009, 23, 1-70.	2.4	683
236	Once-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology, 2009, 219, 239-249.	2.1	48
237	The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. Archives of Dermatological Research, 2008, 300, 537-544.	1.9	45
238	Quality of psoriasis care in Germany â€ results of the national study PsoHealth 2007. JDDG - Journal of the German Society of Dermatology, 2008, 6, 640-645.	0.8	63
239	Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Cross-Sectional Study in Germany. Dermatology, 2008, 216, 366-372.	2.1	237
240	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Journal of the American Academy of Dermatology, 2008, 58, 224-231.	1.2	157
241	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, The, 2008, 371, 1675-1684.	13.7	1,296
242	Consistency of Infliximab Response across Subgroups of Patients with Psoriasis: Integrated Results from Randomized Clinical Trials. Psoriasis Forum, 2007, 13a, 21-27.	0.1	15
243	Costs and quality of life in patients with moderate to severe plaqueâ€ type psoriasis in Germany: A multiâ€ center study. JDDG - Journal of the German Society of Dermatology, 2007, 5, 209-218.	0.8	87
244	Treatment goals in psoriasis. JDDG - Journal of the German Society of Dermatology, 2007, 5, 566-574.	0.8	90
245	German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Archives of Dermatological Research, 2007, 299, 111-138.	1.9	116
246	Use of fumaric acid esters in psoriasis. Indian Journal of Dermatology, Venereology and Leprology, 2007, 73, 133.	0.6	26
247	Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. European Journal of Dermatology, 2007, 17, 381-6.	0.6	28
248	Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study. Dermatology, 2006, 212, 137-144.	2.1	109
249	Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. British Journal of Dermatology, 2006, 154, 1161-1168.	1.5	116
250	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet, The, 2005, 366, 1367-1374.	13.7	975
251	Promoter Polymorphisms of the Genes Encoding Tumor Necrosis Factor-Î± and Interleukin-1Î² are Associated with Different Subtypes of Psoriasis Characterized by Early and Late Disease Onset. Journal of Investigative Dermatology, 2002, 118, 155-163.	0.7	110
252	Methods used for indirect comparisons of systemic treatments for psoriasis. A systematic review. Skin Health and Disease, 0, , .	1.5	2